Results 201 to 210 of about 40,945 (273)

Global Patterns of Fatalities With Toxicological Detection of Novel Psychoactive Substances: A Systematic Review and Meta-analysis. [PDF]

Cureus
Tyagi S, Singh JP, Manzoor A, Basra S, Sharma Y, Sharma P, Shubham, Kaur A, Kaur S.   +8 more
europepmc   +1 more source

Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community. [PDF]

Harm Reduct J
Kruger DJ, Mersereau G, Sullivan A, Barron J, Herberholz M, Pouyan N, Aday JS, Boehnke KF.   +7 more
europepmc   +1 more source

Ecstasy as a Potential Cause for Diffuse ST Elevation in a 27-Year-Old Healthy Male: A Case Report. [PDF]

Cureus
Nasrallah R, Ossaily A, Al Hammoud M, Nader A, Ghanem G.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

MDMA and MDMA-Assisted Therapy

American Journal of Psychiatry
MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an ...
Aaron S, Wolfgang, Gregory A, Fonzo, Joshua C, Gray, John H, Krystal, Adrienne, Grzenda, Alik S, Widge, Nina V, Kraguljac, William M, McDonald, Carolyn I, Rodriguez, Charles B, Nemeroff   +9 more
openaire   +3 more sources

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Nature Medicine, 2021
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial ...
Jennifer M Mitchell, Michael Bogenschutz, Marcela   +2 more
exaly   +2 more sources

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Nature Medicine, 2023
This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post ...
Jennifer M Mitchell, Marcela, Michael Bogenschutz   +2 more
exaly   +2 more sources

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Journal of Psychopharmacology, 2022
Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Before psychedelics become registered medicines, it is important to know the full range of adverse events (AEs ...
Joost J Breeksema, Eric H G J M Vermetten   +1 more
exaly   +2 more sources

Oxytocin-dependent reopening of a social reward learning critical period with MDMA

Nature, 2019
A critical period is a developmental epoch during which the nervous system is expressly sensitive to specific environmental stimuli that are required for proper circuit organization and learning.
Romain Nardou, Rebecca Rothhaas
exaly   +2 more sources

RETRACTED ARTICLE: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials

Psychopharmacology, 2019
Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options.
Allison A Feduccia, Lisa Jerome, Zach Walsh   +2 more
exaly   +2 more sources